Seroatlas · Human Serome Atlas

IL23A

Interleukin-23 subunit alpha

Also known as: IL-23, IL-23A, IL23A_HUMAN, IL23P19, P19, SGRF

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9NPF7
Gene
IL23A
Ensembl
ENSG00000110944
Chromosome
12
Canonical length
189 aa
Protein class
FDA approved drug targets, Predicted secreted proteins
Subcellular location
Cytosol
Secretome location
Secreted to blood

OverviewNCBI Gene

This gene encodes a subunit of the heterodimeric cytokine interleukin 23 (IL23). IL23 is composed of this protein and the p40 subunit of interleukin 12 (IL12B). The receptor of IL23 is formed by the beta 1 subunit of IL12 (IL12RB1) and an IL23 specific subunit, IL23R. Both IL23 and IL12 can activate the transcription activator STAT4, and stimulate the production of interferon-gamma (IFNG). In contrast to IL12, which acts mainly on naive CD4(+) T cells, IL23 preferentially acts on memory CD4(+) T cells. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

189 residues, UniProt reviewed canonical sequence.

>Q9NPF7|IL23A
     1  MLGSRAVMLL LLLPWTAQGR AVPGGSSPAW TQCQQLSQKL CTLAWSAHPL VGHMDLREEG
    61  DEETTNDVPH IQCGDGCDPQ GLRDNSQFCL QRIHQGLIFY EKLLGSDIFT GEPSLLPDSP
   121  VGQLHASLLG LSQLLQPEGH HWETQQIPSL SPSQPWQRLL LRFKILRSLQ AFVAVAARVF
   181  AHGAATLSP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IL23A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.38
Highest tissue expression
42 nTPM

Expression across tissuesHPA

Tissue

  • urinary bladder: 42 nTPM
  • tonsil: 8.2 nTPM
  • thymus: 6.7 nTPM
  • esophagus: 4.3 nTPM
  • testis: 4.2 nTPM
  • lymph node: 4 nTPM

Single-cell type

  • cdc: 55 nCPM
  • epididymal basal cells: 55 nCPM
  • late primary spermatocytes: 38 nCPM
  • early primary spermatocytes: 35 nCPM
  • innate lymphoid cells: 25 nCPM
  • urothelial cells: 23 nCPM

Immune cell

  • naive CD4 T-cell: 28 nTPM
  • memory CD4 T-cell: 26 nTPM
  • naive B-cell: 22 nTPM
  • memory B-cell: 19 nTPM
  • naive CD8 T-cell: 18 nTPM
  • T-reg: 16 nTPM

Brain region

  • hippocampal formation: 1.1 nTPM
  • amygdala: 1 nTPM
  • medulla oblongata: 1 nTPM
  • thalamus: 1 nTPM
  • white matter: 1 nTPM
  • midbrain: 0.9 nTPM

ReferencesPubMed · IEDB

Publications for IL23A from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.71
gnomAD pLI
0.36
gnomAD missense Z
1.19
DepMap mean gene effect
-0.09
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of IL23A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IL23A as an antibody target. Whether an autoantibody or antibody against IL23A could matter depends on whether native IL23A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IL23A is annotated as secreted, so native IL23A circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label IL23A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/IL23A. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...